Masimo (MASI) Expected to Announce Earnings on Tuesday

Masimo (NASDAQ:MASI) is expected to be posting its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect the company to announce earnings of $1.19 per share and revenue of $366.8880 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

Masimo (NASDAQ:MASI) last issued its earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share (EPS) for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The company had revenue of $617.00 million for the quarter. On average, analysts expect Masimo to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Masimo Trading Down 0.6%

Shares of MASI stock opened at $140.65 on Friday. Masimo has a 12-month low of $133.70 and a 12-month high of $194.88. The company has a current ratio of 2.14, a quick ratio of 1.61 and a debt-to-equity ratio of 0.57. The firm’s 50 day moving average is $144.80 and its 200 day moving average is $154.10. The stock has a market capitalization of $7.64 billion, a P/E ratio of -16.51 and a beta of 1.28.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Piper Sandler raised their target price on shares of Masimo from $200.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 6th. Weiss Ratings restated a “sell (d)” rating on shares of Masimo in a report on Wednesday, October 8th. Zacks Research cut shares of Masimo from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. BTIG Research restated a “buy” rating and issued a $198.00 target price on shares of Masimo in a report on Thursday, September 11th. Finally, Wall Street Zen upgraded shares of Masimo from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Masimo currently has an average rating of “Moderate Buy” and an average target price of $194.60.

Insider Activity

In other Masimo news, Director William R. Jellison acquired 3,000 shares of the business’s stock in a transaction dated Monday, August 11th. The stock was purchased at an average price of $145.98 per share, with a total value of $437,940.00. Following the transaction, the director directly owned 4,790 shares in the company, valued at approximately $699,244.20. The trade was a 167.60% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 9.70% of the stock is currently owned by insiders.

Institutional Trading of Masimo

Several institutional investors and hedge funds have recently modified their holdings of MASI. Royal Bank of Canada raised its position in shares of Masimo by 44.5% during the 1st quarter. Royal Bank of Canada now owns 43,884 shares of the medical equipment provider’s stock valued at $7,311,000 after purchasing an additional 13,513 shares during the period. AQR Capital Management LLC raised its position in shares of Masimo by 136.5% during the 1st quarter. AQR Capital Management LLC now owns 8,142 shares of the medical equipment provider’s stock valued at $1,305,000 after purchasing an additional 4,700 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Masimo by 0.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock valued at $1,894,000 after purchasing an additional 66 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Masimo during the 1st quarter valued at $220,000. Finally, Jones Financial Companies Lllp raised its position in shares of Masimo by 1,267.1% during the 1st quarter. Jones Financial Companies Lllp now owns 2,201 shares of the medical equipment provider’s stock valued at $367,000 after purchasing an additional 2,040 shares during the period. 85.96% of the stock is currently owned by institutional investors.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.